Longevity Startup Funding 2025-2026

What are all the funding deals in the longevity market from August 2025 to July 2026?

The table below lists every disclosed equity round raised by pure-play longevity companies between August 2025 and July 2026. We count as “pure-play” longevity companies those focused on products and services that use science, medicine, or technology to extend healthy years of life, slow aging-linked decline, or optimize long-term health.

Each row shows the company, what it does, its category, the deal date, the funding stage, the round size, the region, the main investors, and the announcement source. For a wider view of how longevity fits inside the broader healthspan and preventive health opportunity, we cover it in our Longevity market report.

How active has fundraising been in the longevity market?

As of July 2026, fundraising in the longevity market has been active but selective. Over the past 12 months, pure-play longevity companies raised 20 disclosed equity rounds and $1.14B combined.

That works out to an average of 1.67 deals per month and a median of 1.50 deals per month. So the longevity market is not quiet, but it is not producing a broad wave of monthly financings either.

Capital flow looks much larger than the deal count suggests. The market raised an average of $95.36M per month, but the median month raised only $38M, which shows how strongly large rounds distort the picture.

The best reading is that longevity fundraising is alive, but not evenly distributed. A few companies can raise at scale, while many others remain in smaller Seed and Series A territory.

If you’re interested in the companies and categories behind the total, see our market report covering longevity startups.

How concentrated has fundraising been in the longevity market?

As of July 2026, fundraising in the longevity market has been extremely concentrated. Over the past 12 months, the top deal alone accounted for 38.02% of disclosed capital, while the top 3 deals reached 72.80%.

The top 5 deals reached 80.42% of all capital, and the top 10 reached 90.78%. That means half of the deals explain almost the entire dollar story in the longevity market.

NewLimit’s $435M Series C is the clearest example of this pattern. It is larger than every non-megaround in the dataset combined, and it makes the overall market look more liquid than it is for the median company.

This concentration matters because the longevity market includes very different business models. A reprogramming platform, a preventive health platform, and a skin longevity brand should not be interpreted as the same funding signal.

How much of the longevity funding signal is driven by outliers?

As of July 2026, the longevity funding signal is heavily driven by outliers. Over the past 12 months, three rounds above $50M represented only 15.00% of deals but shaped most of the capital narrative.

The two rounds above $100M were NewLimit’s $435M Series C and Function Health’s $298M Series B. Together, they accounted for more than half of all disclosed funding in the longevity market.

Total capital excluding rounds above $50M falls from $1.14B to $311.28M. That is a major difference, and it gives a better sense of the fundraising environment for most companies.

The average round size is $57.21M, but the median is only $20M. In this market, the median is the safer number for understanding what a typical disclosed round looks like.

Is the longevity market broad with many targets, or narrow with few fundable companies?

As of July 2026, the longevity market is broad in themes but narrow in fundable companies. Over the past 12 months, the dataset includes 20 deals across 18 unique companies.

That company count suggests active formation, but not yet a dense venture ecosystem. The longevity market still depends on a limited number of companies that can translate aging claims into credible products, platforms, or clinical paths.

The category mix shows breadth on the surface. The dataset includes therapeutics, preventive health platforms, consumer longevity brands, aging research platforms, clinics, and diagnostics biomarker companies.

But capital is much narrower than category coverage. Longevity Therapeutics Developers and Preventive Health Platforms together account for 89.69% of disclosed capital, leaving the other four categories with much smaller dollar shares.

Is longevity mostly an early-stage formation market or a late-stage scaling market?

As of July 2026, the longevity market is numerically early-stage but financially late-stage. Over the past 12 months, Seed and Series A rounds represented 13 of 20 deals, but only 17.02% of capital.

Late-stage funding tells the opposite story. Series B and Series C rounds represented only 6 deals, but they captured $929.50M, or 81.23% of all disclosed capital.

This means investors are still testing new longevity ideas, but they reserve large checks for companies with stronger validation. That validation can be clinical proximity, platform credibility, regulatory progress, or consumer distribution at scale.

Seed rounds remain numerous but small. The 7 Seed deals averaged $7.22M, which suggests early investors are funding exploration while waiting for stronger proof before scaling commitments.

For a deeper look at how stage mix shapes the opportunity, read our full market deck on longevity fundraising.

Which categories attract the most investor attention in longevity?

As of July 2026, Longevity Therapeutics Developers attract the most investor attention in the longevity market. Over the past 12 months, they raised 8 deals and $658.03M, or 57.51% of disclosed capital.

Preventive Health Platforms rank second by capital, with 4 deals and $368.25M raised. Their dollar share is 32.18%, which is very high for a category with only one-fifth of total deal count.

Consumer Longevity Brands, Aging Research Platforms, Healthy Aging Clinics, and Diagnostics Biomarker Companies are all visible but smaller. Each has 2 disclosed deals, but none comes close to the funding weight of therapeutics or preventive platforms.

The pattern suggests that the longevity market rewards two kinds of stories. Investors back either pharma-scale biology risk or scalable preventive health platforms with near-term distribution.

Which categories attract disproportionately large checks in the longevity market?

As of July 2026, Preventive Health Platforms attract the most disproportionately large checks in the longevity market. Over the past 12 months, they represented 20.00% of deals but 32.18% of capital, giving them a 1.61 capital share to deal share ratio.

Longevity Therapeutics Developers also attract large checks, with a 1.44 ratio. That is driven by NewLimit, Loyal, Juvena, Junevity, Engitix, Ternary, Gero-linked biology, and other mechanism-led companies.

Diagnostics Biomarker Companies look strategically important but undercapitalized. They represent 10.00% of deals but only 1.40% of capital, which means aging measurement is still mostly a seed-scale funding category.

Healthy Aging Clinics also lag on check size, with 10.00% of deals and only 2.18% of capital. That suggests investors see demand, but high-touch physical care models receive smaller rounds than software-enabled preventive platforms.

Which geographies matter most for fundraising in the longevity market?

As of July 2026, North America matters most for fundraising in the longevity market. Over the past 12 months, it captured $1.02B, or 88.75% of all disclosed capital.

North America also leads on deal count, with 12 of 20 disclosed rounds. But its capital share is much higher than its deal share, which shows that the largest longevity checks remain concentrated in the US ecosystem.

Europe produced 5 deals and $62.40M, equal to 5.45% of disclosed capital. That means Europe is active in company formation, but still small-round biased during this window.

Asia-Pacific produced 3 deals and $66.25M, equal to 5.79% of disclosed capital. The region’s signal is driven mainly by Everlab, Gero, and TMRW rather than a broad funding base.

For more context on regional funding weight, see our deeper analysis of the longevity market.

Is the longevity opportunity set broad or concentrated in one hub?

As of July 2026, the longevity opportunity set is global in formation but concentrated in capital scale. Over the past 12 months, North America, Europe, and Asia-Pacific all produced disclosed deals, but North America dominated dollars.

North America’s median round size was $20M, while its average was $84.64M. That gap reflects the same pattern seen across the whole longevity market: a few large rounds pull up the average.

Europe’s median round size was $8M, and Asia-Pacific’s median was $17M. Both regions are credible, but neither matched North America’s ability to produce very large institutional rounds.

Latin America, the Middle East, and Africa had no disclosed pure-play longevity equity rounds in this dataset. That absence does not mean there is no activity, but it does mean no qualifying public financing appeared in the period.

Is longevity a market of small experiments or scaled financings?

As of July 2026, the longevity market is both a market of small experiments and scaled financings. Over the past 12 months, 9 deals were below $20M, while 3 deals were above $50M.

The middle of the market is also meaningful. Eight deals fell between $20M and under $50M, which makes the $20M to $50M range a key funding band for credible but not yet mega-scale companies.

The megaround rate is only 15.00% of total deals, but those megarounds control the narrative. NewLimit, Function Health, and Loyal show that investors will write large checks when the evidence type is strong enough.

The barbell shape matters. Many Seed and Series A rounds show new formation, while several large Series B and Series C rounds show conviction in a small set of validated platforms.

If you want to compare small experiments with scaled financings, explore our market report on longevity opportunities.

Who are the investors that appear the most in longevity fundraising?

As of July 2026, repeat investors in the longevity market are concentrated around a small set of companies. Over the past 12 months, Eli Lilly and Lilly Ventures appeared across NewLimit and Juvena Therapeutics.

Kleiner Perkins, Human Capital, and Duke Management Company also appeared across NewLimit’s October 2025 and June 2026 rounds. Those repeated appearances show continued conviction in epigenetic reprogramming rather than broad coverage of every longevity category.

NFDG appeared in Function Health and NewLimit, which connects two different funding stories: preventive health distribution and aging-biology therapeutics. Left Lane Capital appeared in Function Health and Everlab, both preventive health platform bets.

General Catalyst is explicit in Lucis’s Series A and has exposure to preventive health through Function Health-related activity where disclosed. Still, the key caveat is that round announcements rarely disclose individual check sizes, so investor repetition should be read as participation, not dollars committed.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.